Congress Can Fix the Dangerous Dependence on Imported Pharmaceuticals
In the wake of the COVID pandemic, consumers have become painfully aware of America’s heavy dependence on imports. The recent Amoxicillin shortage in hospitals has
In the wake of the COVID pandemic, consumers have become painfully aware of America’s heavy dependence on imports. The recent Amoxicillin shortage in hospitals has
Last year, more than 73,000 Americans died from an overdose of the synthetic opioid fentanyl. The drug itself is cheap and readily available, with thousands of pounds flowing into
WASHINGTON — The Coalition for a Prosperous America (CPA) today applauded the introduction of the Producing Incentives for Long-term Production of Lifesaving Supply of Medicines
Chinese solar manufacturers could take advantage of the Inflation Reduction Act’s tax credits by opening plants in the United States.
The following written testimony was submitted by Michael Stumo, CEO of CPA, to the House Homeland Security Subcommittee on Oversight, Investigations, and Accountability in a
The U.S. China Economic & Security Review Commission heard from witnesses about keeping auto tariffs on China, and more incentives for manufacturing to reshore.
Background De minimis is a regulatory loophole. It was morphed from a tiny customs administrative exception into a backdoor superhighway through our ports. The regulatory
In latest House Select Committee on the CCP, outbound investment restrictions get favorable view.
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?